Welcome to our dedicated page for CytoMed Therapeutics SEC filings (Ticker: GDTC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on CytoMed Therapeutics's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into CytoMed Therapeutics's regulatory disclosures and financial reporting.
CytoMed Therapeutics Ltd director and more-than-10% owner Choo Chee Kong filed an initial Form 3 reporting his ownership in the company. The filing shows beneficial ownership of 2,075,310 Ordinary Shares held through Glorious Finance Limited, 194,112 Ordinary Shares held through EP Capital Inc., and 318,324 Ordinary Shares held directly by Mr. Choo. He disclaims beneficial ownership of 1,697,981 Ordinary Shares held by Glorious Finance to the extent he has no economic interest in those shares.
CytoMed Therapeutics Ltd executive Tan Yoong Ying, the Chief Corporate Officer, reported his initial ownership on a Form 3. He holds 25,781 Ordinary Shares with no par value per share, held directly. The filing does not show any recent purchases or sales, only his existing stake.
CytoMed Therapeutics Ltd filed an initial insider ownership report for its Chief Financial Officer, Yvonne Goh. The filing shows she directly holds 25,781 Ordinary Shares of the company. This Form 3 does not report any new share purchases, sales, or option exercises, only her existing stake.
CytoMed Therapeutics Limited reported that its Chairman and Director, Mr. Choo Chee Kong, entered into a binding private share purchase agreement on May 13, 2026 to acquire 112,000 ordinary shares of the company from an independent arm's-length shareholder for cash consideration.
The transaction was a privately negotiated deal between Mr. Choo and the shareholder. The company was not a party to the transaction and did not receive any proceeds. Mr. Choo intends to negotiate privately with additional independent arm's-length shareholders to further increase his shareholding.
CytoMed Therapeutics Limited reports that its wholly owned subsidiary Advance Cancer Centre Pte. Ltd., established in 2020, has been renamed CytoMed International Pte. Ltd., effective May 6, 2026. The new name is meant to reflect a stronger push into international markets.
The company plans to expand its footprint through overseas joint ventures, international medical tourism initiatives, and appointment of overseas representatives, with an initial focus on Asia, especially China, where its allogeneic gamma delta T cell technology is drawing partner interest following China’s Directive 818. The subsidiary currently holds a 19.0% equity interest in a licensed clinic in Malaysia and may increase this stake in the future. The name change does not alter the subsidiary’s legal entity, ownership structure, or contracts, and CytoMed intends to use internal resources to fund this international platform.
CytoMed Therapeutics Limited is convening its Annual General Meeting on May 22, 2026 in Singapore and asking shareholders to vote on ten ordinary resolutions. Routine items include adopting the 2025 Singapore statutory and Form 20-F financial statements, re-electing two directors, ratifying WWC, P.C. and KE Trust PAC as auditors for 2026, and approving directors’ fees of US$70,000.
Shareholders are also asked to approve a waiver from the Singapore Code on Take-overs and Mergers, relying instead on U.S. and Nasdaq rules, and to authorize the board to issue new ordinary shares and related instruments, within applicable laws and Nasdaq Listing Rules, until the next AGM. Voting is restricted to holders of ordinary shares on April 10, 2026 who remain shareholders through May 19, 2026, with each of the 11,832,835 outstanding shares entitled to one vote.
CytoMed Therapeutics reported full-year 2025 revenue and other operating income of US$780,857, up from US$663,786 in 2024, but its audited net loss widened to US$3.11 million from US$1.96 million. Excluding non-cash share-based payments and NASDAQ listing-related costs, the loss would have been US$2.12 million.
Cash and bank balances fell to US$1.63 million as of December 31, 2025, from US$3.87 million a year earlier. Research expenses rose to US$1.72 million, driven by higher consumables, employee benefits and clinical trial spending. Employee benefits expanded to US$723,667, reflecting the first post-IPO share awards.
The company highlighted progress in its allogeneic gamma delta T cell programs. Its ANGELICA CAR-T Phase I trial in Singapore has treated six patients and is moving to the highest dose level, with completion targeted this year. CytoMed also signed an MOU for a Phase I trial in Malaysia using unmodified γδ T cells, co-authored preclinical AML research with MD Anderson Cancer Center, and acquired Malaysian cord blood banking assets to support future cell-based therapies.
CytoMed Therapeutics Limited files its annual report as a clinical-stage biopharmaceutical company focused on novel cell therapies and still operating at a loss.
The Singapore-based Nasdaq-listed issuer had 11,828,435 ordinary shares outstanding as of December 31, 2025 and no products approved for commercial sale. It reports accumulated losses of S$14.85 million as of December 31, 2024 and S$18.83 million as of December 31, 2025, with cash and bank balances declining from S$4.97 million to S$2.10 million over the same dates. Management highlights substantial doubt about its ability to continue as a going concern without additional funding. Research expenses were S$1.91 million in 2024 and S$2.22 million in 2025, reflecting continued investment in a pipeline that includes CTM-N2D, iPSC-gdNKT, CTM-GDT, CTM-MSC and CTM-NK. CytoMed previously raised approximately S$10.31 million (U.S.$7.81 million) in net proceeds from its April 18, 2023 initial public offering and established an at-the-market program on August 18, 2025 to sell up to U.S.$4,304,945 of ordinary shares to support ongoing development and operations.
A GDTC shareholder filed a notice of proposed sale of 117,337 ordinary shares on NASDAQ through Bank of Singapore, with an approximate sale date of February 12, 2026. The filing notes that there were 11,733,712 ordinary shares outstanding at the time.
The seller previously disposed of ordinary shares over the past three months in three transactions, including 22,950 shares for gross proceeds of $43,889.34, 12,005 shares for $19,659.86, and 8,245 shares for $12,908.25. The shares being sold were originally acquired by share subscription from the issuer in April 2021 and paid for in cash.